ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / COYA / insiders
CRBP (34) RANI (30) LFVN (67) CING (34) ⌘ Pro Terminal β†’

Coya Therapeutics Inc. (COYA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.23 -10.53% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.16

Coya Therapeutics Inc. (COYA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $75.8M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on COYA Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is COYA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Coya Therapeutics Inc. (NASDAQ: COYA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.23 (-10.53% 1D, market cap $75.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, COYA ranks #837 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does COYA compare to CRBP and RANI in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COYA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, CRBP (Corbus Pharmaceuticals Holdings Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $75.7M) and RANI (Rani Therapeutics Holdings Inc. (Class A)) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $76.9M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for COYA?
β–Ό

Per COYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835022), Coya Therapeutics Inc. generated $7.9M in revenue (+123.6% YoY), -$21.2M in net income, and -$10.7M in free cash flow against $50.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.16 (-2.09%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (29/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510029
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (9)Whales (3)SEC (11)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
$7 Bull$3 Base$2 Bear
πŸ“¬ FREE COYA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for COYA)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
πŸ” WHY COYA SCORES 29/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (38% of score)

Altman Z-Score 6.08 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–² #2 Bullish Driver: Cash Engine Quality+9/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
37
Grade E$4.47-5.8% Next Q
Q2 (-2Q)
34
Grade E$4.21-2.1% Next Q
Q3 (-1Q)
32
Grade E$4.12-21.6% Next Q
Current
29
Grade E$3.23-9.8% Hist 90D Ξ±
Trajectory: E (37) β†’ E (29)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a COYA Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While COYA currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.55) and Max Pain ($3.39) forces dealer call-delta covering toward $6.95.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $COYAβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œCOYA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

COYA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (COYA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on COYA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring COYA)

  • βœ“Walkthrough of COYA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
COYA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -24.00%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-04O $3.61H $3.61L $3.23C $3.23VOL 270.2K
RES: $4.91SUP: $2.98SMA50: $4.55SMA200: $4.64
$6.42$5.55$4.69$3.83$2.96RES $4.91SUP $2.98$3.232026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

COYA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ COYA Butterfly Map β†’ + Track COYA β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +123.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on COYA today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for COYA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for COYA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COYA)

Health Care Rank #837 of 1015 βš”οΈ CRBP vs COYA Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (COYA vs. CRBP, RANI, LFVN, CING)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Coya Therapeutics Inc. (COYA) ranks #837 by composite RQD confidence (29/100, grade E) and #686 by equity capitalization ($75.8M). Within this direct 5-issuer industry benchmark cohort, LFVN leads on earnings valuation at 7.5x trailing P/E, while LFVN leads on capital efficiency and profitability with 29.2% ROIC and 80.4% gross margin. LFVN currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with COYA at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
COYA ACTIVE
Coya Therapeutics Inc.
E 29/100 β€” β€” -35.0% -10.53% $75.8M Benchmark Subject
CRBP
Corbus Pharmaceuticals Holdings Inc.
E 34/100 β€” β€” -35.0% -7.23% $75.7M /crbp-vs-coya β†’
RANI
Rani Therapeutics Holdings Inc. (Class A)
E 30/100 β€” β€” -35.0% -6.47% $76.9M /rani-vs-coya β†’
LFVN
Lifevantage Corporation (Delaware)
C+ 67/100 7.5x 80.4% 29.2% -0.17% $73.9M /lfvn-vs-coya β†’
CING
Cingulate Inc.
E 34/100 β€” β€” -35.0% +1.00% $73.1M /cing-vs-coya β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001835022 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Coya Therapeutics Inc. (COYA) reported GAAP revenue of $7.9M (+123.6% vs. FY2024 revenue of $3.6M , and +32.4% cumulative change since FY2023) , GAAP net income of -$21.2M, operating cash flow of -$10.7M, and free cash flow of -$10.7M (-4.4% YoY). On the balance sheet, COYA closed FY2025 with $50.0M in total assets against $0 in total debt (Altman Z-Score: 6.08, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $7.9M -$21.2M -$10.7M -$10.7M $50.0M β€”
FY2024 (FY) 2024-12-31 $3.6M -$14.9M -$10.3M -$10.3M $44.3M β€”
FY2023 (FY) 2023-12-31 $6.0M -$8.0M -$11.2M -$11.2M β€” β€”

3. COYA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is COYA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Coya Therapeutics Inc. (NASDAQ: COYA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.23 (-10.53% 1D, market cap $75.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, COYA ranks #837 in composite RQD confidence.

How does COYA compare to CRBP and RANI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COYA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, CRBP (Corbus Pharmaceuticals Holdings Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $75.7M) and RANI (Rani Therapeutics Holdings Inc. (Class A)) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $76.9M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for COYA?

Per COYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835022), Coya Therapeutics Inc. generated $7.9M in revenue (+123.6% YoY), -$21.2M in net income, and -$10.7M in free cash flow against $50.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is COYA trading relative to its 50-day, 200-day, and 52-week technical levels?

COYA last traded at $3.23 (-10.53% on volume of 270,206 shares), positioning the stock -29.01% below its 50-day simple moving average ($4.55) and -30.39% below its 200-day simple moving average ($4.64). Across its 52-week range of $3.23 to $6.62, COYA sits at the 0.0% percentile with a 14-day RSI of 22.0 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($2.83 to $3.63).

Direct Sub-Reports: COYA RQD Cockpit COYA 12M Forecast COYA Earnings & Move COYA Dividends & DRIP COYA Insiders & 13F COYA Whale Options COYA Profit Sankey COYA News & Why
ROARABLE RATING BRIEF β€’ RQD 29/100 (E) βœ“ SEC XBRL & RQD VERIFIED

COYA β€” Coya Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Coya Therapeutics Inc. (COYA) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.23 (-10.53% 1D, market capitalization $75.8M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of -11.50%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 6.08, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Coya Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..1B. Per the financials, it reported revenue of $7.9M in FY 2025, indicating some commercial or collaborative revenue base. β€”: product lines, customer categories, and specific revenue model details.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Coya Therapeutics Inc. (COYA) reported $7.9M in annual revenue (up from $3.6M in FY2024, +123.6% YoY) and -$21.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.0M revenue, -$8.0M net income) through FY2025, COYA scaled operating cash flow to -$10.7M and free cash flow to -$10.7M, backed by $50.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -11.50% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.23 – $6.62 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be mapped from the source data. The sector correlation is limited to Health Care and the Biotechnology: Pharmaceutical Preparations industry. The 2nd-order item to watch is trial-timing risk: the RED-flagged delay in another trial's start shows that pipeline sequencing, rather than a supply chain, is the more visible ripple channel in the source material.

  • Key Question #1: Can COYA sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $7.9M and free cash flow of -$10.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is COYA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

COYA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Coya Therapeutics Inc. (COYA) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to COYA Debate Forum (3) ↓
🟑 MARKET WIRE Benzinga β€’ 7d ago
Coya Therapeutics To Highlight ALS Data In Poster Presentation At 2026 Annual NEALS Meeting; Co. Currently Conducts ALSTARS Trial, Phase 2/3, Study To Evaluate COYA 302 For ALS Treatment

ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individualsThe Company believes implementation of a prospective

Read Full Source β†—
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

COYA Bull vs. Bear Conversation Board β€” What's Your Call at $3.23?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON COYA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on COYA:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $4.48 (+24.1%)
πŸ“Œ Pinned Debate

Full enrollment in the Phase 2/3 ALSTARS trial of COYA 302 and a reiterated Buy rating from H.C. Wainwright point to pipeline progress.

Here is why I am bullish on COYA here at $3.61: Full enrollment in the Phase 2/3 ALSTARS trial of COYA 302 and a reiterated Buy rating from H.C. Wainwright point to pipeline progress.. Compare COYA's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $3.43 are getting bought.

SectorRotator πŸ‚ BULL

@QuantViper Agree on the RQD 29/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.61 and keeping dry powder in case we test $3.36.

MU MultipleCompression RQD DEBATE OPENER β€’ Valuation Discipline 🐻 BEARISH 🎯 Target: $2.85 (-21.1%)
Spot @ $3.61

The RQD score of 35 reflects ROIC of -35%, an FCF yield of -11.5%, and a RED-flagged trial-start delay with a share price down 9.3%.

Sitting on the sidelines or leaning short COYA above $3.61. The RQD score of 35 reflects ROIC of -35%, an FCF yield of -11.5%, and a RED-flagged trial-start delay with a share price down 9.3%.. Until Fundamental Cash Engine (9/20) and FCF yield (-11.5%) inflect higher, upside is capped near $6.62.

LIVE TAPE